Announcements Trials
Browse Landscape

Phase

Phase 3 10Phase 2 4Phase 1 3

Status

Completed 3

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Hormone Treatment-naïve Participants With Prostate Cancer 1Endometriosis 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × relugolix × Clear all
NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

Sumitomo Pharma America, Inc.

Phase 1 Completed
48 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02141659 2018-11-19

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

Takeda

Phase 1 Completed
43 enrolled 23 charts
Genitourinary

Hormone Treatment-naïve Participants With Prostate Cancer

NCT02093390 2016-06-06

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
40 enrolled 23 charts
Genitourinary

Endometriosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡